- Home
- AQMS vs GLTO Comparison
AQMS vs GLTO Comparison
Compare AQMS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- GLTO
- Stock Information
- Founded
- AQMS 2014
- GLTO 2011
- Country
- AQMS United States
- GLTO Denmark
- Employees
- AQMS N/A
- GLTO N/A
- Industry
- AQMS Metal Fabrications
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- AQMS Industrials
- GLTO Health Care
- Exchange
- AQMS Nasdaq
- GLTO Nasdaq
- Market Cap
- AQMS 5.1M
- GLTO 4.5M
- IPO Year
- AQMS 2015
- GLTO 2020
- Fundamental
- Price
- AQMS $3.75
- GLTO $3.18
- Analyst Decision
- AQMS Buy
- GLTO Buy
- Analyst Count
- AQMS 1
- GLTO 1
- Target Price
- AQMS $30.00
- GLTO $10.00
- AVG Volume (30 Days)
- AQMS 35.1K
- GLTO 8.2K
- Earning Date
- AQMS 08-13-2025
- GLTO 10-31-2025
- Dividend Yield
- AQMS N/A
- GLTO N/A
- EPS Growth
- AQMS N/A
- GLTO N/A
- EPS
- AQMS N/A
- GLTO N/A
- Revenue
- AQMS N/A
- GLTO N/A
- Revenue This Year
- AQMS N/A
- GLTO N/A
- Revenue Next Year
- AQMS $550.00
- GLTO N/A
- P/E Ratio
- AQMS N/A
- GLTO N/A
- Revenue Growth
- AQMS N/A
- GLTO N/A
- 52 Week Low
- AQMS $3.37
- GLTO $2.01
- 52 Week High
- AQMS $46.00
- GLTO $14.82
- Technical
- Relative Strength Index (RSI)
- AQMS 44.14
- GLTO 35.58
- Support Level
- AQMS $3.55
- GLTO $2.95
- Resistance Level
- AQMS $4.35
- GLTO $3.28
- Average True Range (ATR)
- AQMS 0.31
- GLTO 0.11
- MACD
- AQMS 0.10
- GLTO -0.03
- Stochastic Oscillator
- AQMS 38.78
- GLTO 23.98
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.